Neuralink Stock
Private company — Neuralink is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.
Status source: AXEVIL investment team
$286.73 per share (AXEVIL consensus estimate)
Source: AXEVIL consensus of recent secondary transactions · as of 11 August 2026
Valuation: $54.19B
Source: E, June 2025 — post-money $9.65B
Total raised: $1.2B
Data last updated: 11 August 2026
About Neuralink
Leader in neurochips — brain-computer interfaces for treating neurological disease and enhancing cognition.
Neuralink, founded by Elon Musk, is the leader in implantable brain-computer interfaces: 12 patients control computers and robotic arms by thought, with 15,000+ hours of implant operation and trials in 4 countries. 2026 brings the shift to mass production of implants and fully automated surgery, the launch of Blindsight (vision restoration), and an announced hearing-restoration program. Total addressable market exceeds $400B.
- Sector: Healthcare & Biotech
- Headquarters: Fremont, California
- Founded: 2016
Funding rounds
| Date | Round | Price / share | Post-money valuation |
|---|---|---|---|
| 2 June 2025 | E | $49.09 | $9.65B |
| 22 November 2023 | D | $19.03 | $3.49B |
| 30 July 2021 | C | $13.74 | $2.15B |
| 10 May 2019 | B | $3.82 | $575M |
| 25 August 2017 | A | $1.00 | $143M |
Latest news
- Musk: Neuralink will begin the first implantations of the Blindsight visual prosthesis within a year — 4 August 2026
- Neuralink demonstrated wheelchair control by thought, valuation reached 42 billion dollars — 24 July 2026
- China became the world's first to implant a commercial brain implant, surpassing Neuralink — 16 July 2026
- Neuralink implants its device in the first Canadian ALS patient — 2 July 2026
- Samsung wins Neuralink's first order for a 4nm-process 4th-generation chip — 15 June 2026
- Neuralink shows patient results and unveils Blind Sight, an implant for restoring vision — 16 April 2026
Frequently asked questions
Can I buy Neuralink stock?
Not on a public exchange — Neuralink is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.
How much is one Neuralink share?
A private company has no single official price. AXEVIL's consensus estimate is $286.73 per share as of 11 August 2026. Its most recent round implied a post-money valuation of $9.65B (June 2025).
When will Neuralink IPO?
No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.
Is Neuralink publicly traded?
No. Neuralink is a private company and its shares are not listed on any public exchange.
Similar companies
- Benchling — Healthcare & Biotech
Risk disclosure
Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Valuations and share prices shown here are AXEVIL estimates built from primary sources — filings, announced rounds and completed secondary transactions — not quoted market prices, and they can be revised. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.